Herpes Zoster (Shingles) - Pipeline Review, H2 2020
Herpes Zoster (Shingles) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster - Pipeline Review, H2 2020, provides an overview of the Herpes Zoster (Infectious Disease) pipeline landscape.
Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Herpes Zoster (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Herpes Zoster (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Herpes Zoster (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster - Pipeline Review, H2 2020, provides an overview of the Herpes Zoster (Infectious Disease) pipeline landscape.
Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Herpes Zoster (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Herpes Zoster (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 7, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Herpes Zoster (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Herpes Zoster (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Herpes Zoster (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shulov Innovative Science Ltd
Vaccitech Ltd
Vapogenix Inc
XBiotech Inc
Herpes Zoster (Shingles) - Drug Profiles
B-1006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varicella zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigational vaccine for Shingles CRV-101
Jul 23, 2020: CHMP recommended extension of indication for Shingrix
May 14, 2020: NanoViricides provides update on drug candidate NV-HHV-101
Mar 10, 2020: First QS-21 royalty payment due to Agenus is triggered
Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
Aug 26, 2019: NanoViricides advancing rapidly towards first IND
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shulov Innovative Science Ltd
Vaccitech Ltd
Vapogenix Inc
XBiotech Inc
Herpes Zoster (Shingles) - Drug Profiles
B-1006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CRV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSB-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
varicella zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTP-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigational vaccine for Shingles CRV-101
Jul 23, 2020: CHMP recommended extension of indication for Shingrix
May 14, 2020: NanoViricides provides update on drug candidate NV-HHV-101
Mar 10, 2020: First QS-21 royalty payment due to Agenus is triggered
Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
Aug 26, 2019: NanoViricides advancing rapidly towards first IND
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Herpes Zoster (Shingles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Herpes Zoster (Shingles) - Pipeline by Akshaya Bio Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by GC Pharma, H2 2020
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2020
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2020
Herpes Zoster (Shingles) - Dormant Projects, H2 2020
Herpes Zoster (Shingles) - Discontinued Products, H2 2020
Number of Products under Development for Herpes Zoster (Shingles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Herpes Zoster (Shingles) - Pipeline by Akshaya Bio Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by GC Pharma, H2 2020
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H2 2020
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H2 2020
Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, H2 2020
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H2 2020
Herpes Zoster (Shingles) - Dormant Projects, H2 2020
Herpes Zoster (Shingles) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Herpes Zoster (Shingles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
Akshaya Bio Inc
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shulov Innovative Science Ltd
Vaccitech Ltd
Vapogenix Inc
XBiotech Inc
Number of Products under Development for Herpes Zoster (Shingles), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
Akshaya Bio Inc
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
CPL Biologicals Pvt Ltd
DongKoo Bio & Pharma Co Ltd
GC Pharma
GeneOne Life Science Inc
GlaxoSmithKline Plc
NAL Pharmaceuticals Ltd
NanoViricides Inc
Shulov Innovative Science Ltd
Vaccitech Ltd
Vapogenix Inc
XBiotech Inc
